ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BLSM / earnings
PRTA (23) CRMD (59) KMDA (46) ASMB (16) ⌘ Pro Terminal →

BlossomHill Therapeutics Inc. (BLSM) Next Earnings Date & Expected ±12.5% Move

$12.42 -9.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.18

BlossomHill Therapeutics Inc. (BLSM) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $437.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BLSM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BLSM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BlossomHill Therapeutics Inc. (NASDAQ: BLSM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $12.42 (-9.67% 1D, market cap $437.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BLSM compare to PRTA and CRMD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLSM carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRTA (Prothena Corporation plc) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $434.8M) and CRMD (CorMedix Inc.) posts a C- grade (59/100 RQD, P/E 3.7x, ROIC 45.5%, cap $443.9M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BLSM?
▼

Per BLSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001839970), BlossomHill Therapeutics Inc. generated $68.4M in revenue, $0 in net income, and $0 in free cash flow against $163.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $12.18 (-1.93%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 17.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510042
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D
Cash (10)Whales (3)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
$29 Bull$12 Base$9 Bear
📬 FREE BLSM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BLSM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY BLSM SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 17.9% FCF Margin ($12.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
50
Grade C-$15.48-7% Next Q
Q2 (-2Q)
47
Grade D$14.40+9.4% Next Q
Q3 (-1Q)
45
Grade D$15.76-21.2% Next Q
Current
42
Grade D-$12.42-7% Hist 90D α
Trajectory: C- (50) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BLSM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BLSM currently carries a cautious 42/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.91) and Max Pain ($13.04) forces dealer call-delta covering toward $29.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BLSM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BLSM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 42%NO 58%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.55 Expected Swing
$10.87 (-12.5%)Spot $12.42$13.97 (+12.5%)
MODEL EARNINGS SETUP GAUGE

BLSM Quantitative Pre-Earnings Setup: 42/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (42/100)Model Risk Weight (58/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$68.4M$0$052%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BLSM)

  • ✓Walkthrough of BLSM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BLSM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.38%▼ DESCENDING CHANNEL
2026-11-03O $15.21H $15.21L $12.42C $12.42VOL 156.3K
RES: $17.06SUP: $9.62SMA50: $18.91SMA200: $18.38
$29.08$24.56$20.05$15.53$11.02RES $17.06SUP $9.62$12.422026-08-072026-08-282026-09-212026-10-122026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BLSM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BLSM Butterfly Map → + Track BLSM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BLSM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BLSM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BLSM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLSM)

Health Care Rank #423 of 1015 ⚔️ PRTA vs BLSM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BLSM vs. PRTA, CRMD, KMDA, ASMB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BlossomHill Therapeutics Inc. (BLSM) ranks #423 by composite RQD confidence (42/100, grade D-) and #463 by equity capitalization ($437.0M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while CRMD leads on capital efficiency and profitability with 45.5% ROIC and 88.5% gross margin. CRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with BLSM at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BLSM ACTIVE
BlossomHill Therapeutics Inc.
D- 42/100 — — — -9.67% $437.0M Benchmark Subject
PRTA
Prothena Corporation plc
E 23/100 — — -35.0% -2.12% $434.8M /prta-vs-blsm →
CRMD
CorMedix Inc.
C- 59/100 3.7x 88.5% 45.5% -5.36% $443.9M /crmd-vs-blsm →
KMDA
Kamada Ltd.
D 46/100 — — — -4.42% $444.4M /kmda-vs-blsm →
ASMB
Assembly Biosciences Inc.
E 16/100 — — -6.5% -3.08% $409.9M /asmb-vs-blsm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001839970 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BlossomHill Therapeutics Inc. (BLSM) reported GAAP revenue of $68.4M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BLSM closed FY2025 with $163.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $68.4M $0 — — $163.0M —

3. BLSM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BLSM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BlossomHill Therapeutics Inc. (NASDAQ: BLSM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $12.42 (-9.67% 1D, market cap $437.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does BLSM compare to PRTA and CRMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLSM carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRTA (Prothena Corporation plc) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $434.8M) and CRMD (CorMedix Inc.) posts a C- grade (59/100 RQD, P/E 3.7x, ROIC 45.5%, cap $443.9M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BLSM?

Per BLSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001839970), BlossomHill Therapeutics Inc. generated $68.4M in revenue, $0 in net income, and $0 in free cash flow against $163.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BLSM trading relative to its 50-day, 200-day, and 52-week technical levels?

BLSM last traded at $12.42 (-9.67% on volume of 140,771 shares), positioning the stock -34.32% below its 50-day simple moving average ($18.91) and -32.43% below its 200-day simple moving average ($18.38). Across its 52-week range of $12.93 to $27.99, BLSM sits at the 0.0% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.87 to $13.97).

Direct Sub-Reports: BLSM RQD Cockpit BLSM 12M Forecast BLSM Earnings & Move BLSM Dividends & DRIP BLSM Insiders & 13F BLSM Whale Options BLSM Profit Sankey BLSM News & Why
ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BLSM — BlossomHill Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BlossomHill Therapeutics Inc. (BLSM) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $12.42 (-9.67% 1D, market capitalization $437.0M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

BlossomHill Therapeutics Inc. (BLSM) is a NASDAQ-listed company in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. The profile does not describe its specific products, customers, or revenue model. —: product portfolio details, customer base, and monetization structure.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BlossomHill Therapeutics Inc. (BLSM) reported $68.4M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $163.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $12.93 – $27.99 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers and downstream customers are therefore — The sector is Health Care and the industry is Biotechnology: Pharmaceutical Preparations, but no sector correlation figures beyond the macro liquidity signal are provided. The main second-order channel visible in the data is macro liquidity: the signal indicates that tightening liquidity conditions could amplify downside for a stock with a 6.00x net-liquidity elasticity. Investors should watch whether the collaboration tied to BH-30643 progresses, since it is the only documented route to future commercial relevance in the source data.

  • Key Question #1: Can BLSM sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $68.4M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BLSM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BLSM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BlossomHill Therapeutics Inc. (BLSM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BLSM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BLSM Bull vs. Bear Conversation Board — What's Your Call at $12.42?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BLSM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BLSM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $15.81 (+15.0%)
📌 Pinned Debate

The Forensic Balance Sheet pillar scores 13 / 20 with cash of $136.7M and a Debt/Equity of 0.5, and the BH-30643 companion diagnostic c

The Forensic Balance Sheet pillar scores 13 / 20 with cash of $136.7M and a Debt/Equity of 0.5, and the BH-30643 companion diagnostic collaboration offers a potential commercial catalyst.. When you look under the hood at BLSM, Fundamental Cash Engine is 10/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $27.99. My 12M target is $15.81.

CapAlloc_Nerd 🐂 BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $10.59 (-23.0%)
Spot @ $13.75

With ROIC and FCF yield at 0% and whale flow scored 3 / 20, the stock lacks cash returns and institutional support while a bearish liqu

Careful chasing BLSM at $13.75. With ROIC and FCF yield at 0% and whale flow scored 3 / 20, the stock lacks cash returns and institutional support while a bearish liquidity signal at severity 94 points to macro headwinds.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $10.59 on multiple compression.

LIVE TAPE